Financial Performance - Black Diamond Therapeutics reported a net loss of 23.0 million in Q3 2023, representing a 32.6% improvement[6]. - Cash, cash equivalents, and investments totaled approximately 131.4 million at the end of 2023[6][10]. - Total operating expenses for Q3 2024 were 24.0 million in Q3 2023, reflecting a 24.6% decrease[11]. Research and Development - Research and development expenses decreased to 16.2 million in Q3 2023, a reduction of 20.3%[6][11]. - The overall response rate (ORR) for BDTX-1535 in patients with osimertinib-resistant EGFR mutations was reported at 42%[3]. - The duration of response (DOR) for the first three patients achieving a partial response was approximately eight months or more[3]. - 36% of newly diagnosed NSCLC patients with non-classical EGFR mutations received osimertinib or afatinib, while 60% received chemotherapy and/or immunotherapy[3]. - Black Diamond plans to provide clinical updates on BDTX-1535 in Q1 2025, including feedback on a registrational path from the FDA[2][4]. Strategic Initiatives - The company expects its cash runway to extend into Q2 2026, following a corporate restructuring plan aimed at optimizing development resources[5][7]. - Black Diamond is actively seeking partnerships for its deprioritized Phase 1 RAS/RAF inhibitor, BDTX-4933[5].
Black Diamond Therapeutics(BDTX) - 2024 Q3 - Quarterly Results